Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer

AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer

ReutersReuters2026/07/16 10:32
By:Reuters

- AtaiBeckley ATAI.O shares soared 50% premarket on Thursday after a report that Eli Lilly LLY.N was in talks to acquire the psychedelic drug developer as soon as this week.

Bloomberg News, late on Wednesday, said Lilly was negotiating a deal ​at a premium, citing people familiar with the matter.

New York-based AtaiBeckley's shares have gained 31% so far this year to give it a market value of $1.97 billion as of Wednesday's close, according to LSEG data.

U.S. President ​Donald Trump's executive order in April to help speed up access to treatment based on psychedelic ‌drugs had sparked an industrywide rally.

"While the deal could reach more than $2 billion, ongoing talks with additional pharmaceutical companies could support a higher takeout price," said BMO Capital Markets analyst Evan Seigerman.

Lilly shares were flat before the bell.

Eli Lilly and AtaiBeckley were not immediately available for comment outside regular business hours.

Shares of other psychedelic drug developers also rose premarket on Thursday. Compass Pathways CMPS.O gained 7%, GH Research GHRS.O jumped 15%, Definium Therapeutics DFTX.O climbed 6% and Enveric Biosciences ENVB.O rose 3%.

AtaiBeckley focuses on psychedelic-based treatments for mental health conditions and is developing BPL-003, an intranasal formulation of 5-MeO-DMT for treatment-resistant depression.

Trump's order is expected to shorten administrative timelines while attracting more capital to the industry, analysts and health experts have said.

RBC Capital Markets analyst Brian Abrahams said the psychedelic sector is likely to continue its rally and is poised to emerge into the mainstream.

Lilly has been on an acquisition spree, especially in the neuroscience space, highlighted by the $7.8 billion buyout of sleep-disorder drugmaker Centessa Pharmaceuticals.



(Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila)

((Christy.Santhosh@thomsonreuters.com;))

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The AI super bull market still has room for imagination, but Wall Street has quietly prepared "two types of insurance": to guard against slow declines eroding returns, as well as to protect from sudden crashes.

Due to rising interest rates and oil prices causing the stock market rally to stall, investors are divided—some worry about a rapid sell-off, while others are concerned about a slow market decline. Some traders have become more creative with bearish strategies, such as buying put options on the Chicago Board Options Exchange Volatility Index or the S&P 500, or using double binary options to bet on a gradual price drop.

智通财经2026/09/13 23:41
The AI super bull market still has room for imagination, but Wall Street has quietly prepared "two types of insurance": to guard against slow declines eroding returns, as well as to protect from sudden crashes.